Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neucardin in HFpEF on standard heart failure therapy
ChiCTR2000030769Phase 2Recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of neucardin in heart failure with preserved ejection fraction (HFpEF) (4 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Change in peak VO2 from baseline at day 30. Started Feb 2020; status: recruiting.
02
Drugs
neucardin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ChiCTR2000030769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030769.